SI1185529T1 - Pyrazolobenzodiazepines as cdk2 inhibitors - Google Patents

Pyrazolobenzodiazepines as cdk2 inhibitors

Info

Publication number
SI1185529T1
SI1185529T1 SI200030524T SI200030524T SI1185529T1 SI 1185529 T1 SI1185529 T1 SI 1185529T1 SI 200030524 T SI200030524 T SI 200030524T SI 200030524 T SI200030524 T SI 200030524T SI 1185529 T1 SI1185529 T1 SI 1185529T1
Authority
SI
Slovenia
Prior art keywords
pyrazolobenzodiazepines
cdk2 inhibitors
cdk2
inhibitors
Prior art date
Application number
SI200030524T
Other languages
English (en)
Slovenian (sl)
Inventor
Qingjie Ding
Jin-Jun Liu
Vincent Stewart Madison
Giacomo Pizzolato
Chung-Chen Wei
Peter Michael Wovkulich
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI1185529T1 publication Critical patent/SI1185529T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/22—Sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SI200030524T 1999-04-21 2000-04-14 Pyrazolobenzodiazepines as cdk2 inhibitors SI1185529T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13037099P 1999-04-21 1999-04-21
PCT/EP2000/003394 WO2000064900A1 (en) 1999-04-21 2000-04-14 Pyrazolobenzodiazepines as cdk2 inhibitors
EP00929360A EP1185529B1 (en) 1999-04-21 2000-04-14 Pyrazolobenzodiazepines as cdk2 inhibitors

Publications (1)

Publication Number Publication Date
SI1185529T1 true SI1185529T1 (en) 2005-02-28

Family

ID=22444382

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030524T SI1185529T1 (en) 1999-04-21 2000-04-14 Pyrazolobenzodiazepines as cdk2 inhibitors

Country Status (33)

Country Link
US (3) US6440959B1 (ja)
EP (1) EP1185529B1 (ja)
JP (1) JP3746680B2 (ja)
KR (1) KR100481757B1 (ja)
CN (2) CN1196703C (ja)
AR (1) AR023542A1 (ja)
AT (1) ATE279413T1 (ja)
AU (1) AU768667B2 (ja)
BR (1) BR0009887A (ja)
CA (1) CA2367704C (ja)
CO (1) CO5170444A1 (ja)
CZ (1) CZ20013738A3 (ja)
DE (1) DE60014893T2 (ja)
DK (1) DK1185529T3 (ja)
ES (1) ES2228522T3 (ja)
HK (1) HK1046278B (ja)
HR (1) HRP20010742A2 (ja)
HU (1) HUP0300318A3 (ja)
IL (1) IL145764A0 (ja)
JO (1) JO2248B1 (ja)
MA (1) MA26782A1 (ja)
NO (1) NO20015065D0 (ja)
NZ (1) NZ514523A (ja)
PE (1) PE20010054A1 (ja)
PL (1) PL200933B1 (ja)
PT (1) PT1185529E (ja)
RU (1) RU2249593C2 (ja)
SI (1) SI1185529T1 (ja)
TR (1) TR200103016T2 (ja)
TW (1) TW585866B (ja)
WO (1) WO2000064900A1 (ja)
YU (1) YU73101A (ja)
ZA (1) ZA200108016B (ja)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL370176A1 (en) * 2001-11-13 2005-05-16 3-Dimensional Pharmaceuticals, Inc. Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
CA2515790C (en) * 2003-02-27 2012-11-27 Abbott Laboratories Heterocyclic kinase inhibitors
CN101899049A (zh) * 2004-10-13 2010-12-01 霍夫曼-拉罗奇有限公司 二取代吡唑并苯并二氮杂*类
BRPI0617252A2 (pt) * 2005-10-14 2011-07-19 Hoffmann La Roche regime de administração para benzodiazepina 5-2-clorofenil)-1,2-diidro-7-flìor-8-metóxi-3-metil-pira zolo [3,4-b] [1,4]
KR20090045233A (ko) 2006-07-10 2009-05-07 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
SG11201404596UA (en) * 2012-02-02 2014-10-30 Senex Biotechnology Inc Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
CN103288828A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-6H-吲哚并[2,1-c][1,4]-苯并二氮杂卓的方法
CN103288830A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-5H-吡咯并[2,1-c][1,4]-苯并二氮杂卓的方法
CN102603743B (zh) * 2012-02-24 2014-05-28 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
CN106608877B (zh) * 2015-10-21 2018-11-13 新发药业有限公司 一种依鲁替尼中间体4-氨基-3-（4-苯氧基）苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
EP3535253A1 (en) * 2016-11-01 2019-09-11 H. Hoffnabb-La Roche Ag 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of cns related diseases
WO2018108079A1 (zh) 2016-12-13 2018-06-21 南京药捷安康生物科技有限公司 多激酶抑制剂化合物、其晶型及用途
CN109020980B (zh) * 2017-06-09 2020-11-20 华东师范大学 一类抗肿瘤作用的吡唑并嘧啶二氮*衍生物
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223558A1 (en) * 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
KR20220064369A (ko) 2019-08-14 2022-05-18 인사이트 코포레이션 Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물
BR112022006977A2 (pt) 2019-10-11 2022-09-20 Incyte Corp Aminas bicíclicas como inibidores de cdk2
CN113620949A (zh) * 2020-05-08 2021-11-09 南京药捷安康生物科技有限公司 抗肿瘤化合物的合成方法及其中间体
AR124154A1 (es) 2020-11-27 2023-02-22 Rhizen Pharmaceuticals Ag Inhibidores de cdk
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
JP2024517309A (ja) * 2021-05-10 2024-04-19 薬捷安康（南京）科技股▲分▼有限公司 マルチキナーゼ阻害剤の医薬組成物および使用
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024030399A2 (en) * 2022-08-02 2024-02-08 Lab1636, Llc Use of a gaba-a pam for reduction of tactile hypersensitivity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4205168B2 (ja) 1996-10-02 2009-01-07 ノバルティス アクチエンゲゼルシヤフト ピリミジン誘導体およびその製造法
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers

Also Published As

Publication number Publication date
CN1279029C (zh) 2006-10-11
CN1603314A (zh) 2005-04-06
PL200933B1 (pl) 2009-02-27
NO20015065L (no) 2001-10-18
JP2002543081A (ja) 2002-12-17
HK1046278B (zh) 2005-08-12
AR023542A1 (es) 2002-09-04
US20020183514A1 (en) 2002-12-05
US6838558B2 (en) 2005-01-04
DE60014893T2 (de) 2005-10-13
YU73101A (sh) 2004-05-12
IL145764A0 (en) 2002-07-25
ES2228522T3 (es) 2005-04-16
CA2367704C (en) 2008-06-17
EP1185529B1 (en) 2004-10-13
KR100481757B1 (ko) 2005-04-11
HK1046278A1 (en) 2003-01-03
CZ20013738A3 (cs) 2002-08-14
PL354405A1 (en) 2004-01-12
NO20015065D0 (no) 2001-10-18
CN1348455A (zh) 2002-05-08
TR200103016T2 (tr) 2002-04-22
PE20010054A1 (es) 2001-02-07
BR0009887A (pt) 2002-01-22
CA2367704A1 (en) 2000-11-02
DK1185529T3 (da) 2005-02-07
AU4748000A (en) 2000-11-10
JO2248B1 (en) 2004-10-07
PT1185529E (pt) 2005-02-28
DE60014893D1 (de) 2004-11-18
HUP0300318A3 (en) 2004-11-29
ZA200108016B (en) 2003-03-26
JP3746680B2 (ja) 2006-02-15
HUP0300318A2 (hu) 2003-06-28
US20040198976A1 (en) 2004-10-07
EP1185529A1 (en) 2002-03-13
US6440959B1 (en) 2002-08-27
TW585866B (en) 2004-05-01
NZ514523A (en) 2003-11-28
RU2249593C2 (ru) 2005-04-10
AU768667B2 (en) 2003-12-18
HRP20010742A2 (en) 2002-12-31
CO5170444A1 (es) 2002-06-27
ATE279413T1 (de) 2004-10-15
KR20010112435A (ko) 2001-12-20
MA26782A1 (fr) 2004-12-20
CN1196703C (zh) 2005-04-13
US6916923B2 (en) 2005-07-12
WO2000064900A1 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
IL145764A0 (en) Pyrazolobenzodiazepines as cdk2 inhibitors
HUP0202713A3 (en) Pteridinones as kinase inhibitors
GB9900416D0 (en) Inhibitors
SI1686119T1 (sl) Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
IL146518A0 (en) Metalloprotease inhibitors
EG23979A (en) Renin inhibitors
IL145085A0 (en) Dihetero-substituted metalloprotease inhibitors
PL354979A1 (en) Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
ZA200110053B (en) Factor via inhibitors.
IL148275A0 (en) Substituted 3-phenyl-5-alkoxy-1, 3, 4-oxdiazol-2-ones- and their use as lipase inhibitors
GB9924522D0 (en) Enzyme inhibitors
HK1042695A1 (zh) 蛋白酶抑制劑
PL350941A1 (en) Pyrazole-3-on-derivative as factor xa inhibitors
GB0030284D0 (en) Enzyme inhibitors
GB2389113B (en) B-secretase inhibitor
EP1189618A4 (en) thrombin
GB0109278D0 (en) Enzyme inhibitors
AU2002400A (en) Telomerase inhibitors
GB9929340D0 (en) Inhibitors
GB9917294D0 (en) Inhibitors
GB9929341D0 (en) Inhibitors
GB9900413D0 (en) Inhibitors
SI1181017T1 (en) Metalloprotease inhibitors
GB0102194D0 (en) Enzyme inhibitors
GB0101537D0 (en) Enzyme inhibitors